Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 4 | Biomarker Research

Fig. 4

From: Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools

Fig. 4

Schematic representation of the evolution of the CAR structure from the first generation to the fifth. First CAR generation contains only a CD3ζ signaling domain and no co-stimulatory molecules (CMs). Second generation CAR adds one CM to CD3ζ, enabling dual signaling. Third generation CAR combines CD3ζ with multiple CMs to enhance signaling. The fourth-generation CAR, like the 2G CAR, features an NFAT-responsive cassette that triggers cytokine expression, delivering triple signaling through CD3ζ, CM, and transgenic proteins. The fifth generation of CAR, rely on 2G CAR and integrates IL-2Rβ receptors, which activates the JAK-STAT signaling domain for synergistic activation of CD3ζ, CMs, and the JAK-STAT3/5 pathway

Back to article page